Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis

Journal of Magnetic Resonance Imaging

Volumn 7, Issue 1, 1997, Pages 29-37

  Simon, Jack H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Blood brain barrier; Contrast enhanced MR imaging (MRI); Multiple sclerosis

Indexed keywords

GADOLINIUM;

BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PRIORITY JOURNAL; REVIEW; SPINAL CORD; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANIMALS; CLINICAL TRIALS; CONTRAST MEDIA; EVALUATION STUDIES; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OPTIC NERVE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPINAL CORD; TREATMENT OUTCOME;

EID: 0031404155     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880070106     Document Type: Review

References (74)

1. Kurtzke, JF. Epidemiology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of clinical neurology: demyelinating diseases. Amsterdam: Elsevier Science Publishers, 1985; 259-287.
2. Matthews WB. Clinical aspects. In: Matthews WB, ed. McAlpine's multiple sclerosis. New York: Churchill Livingstone, 1985; 49-72.
3. IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661.
4. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45:1277-1285.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294.
6. Paty DW, Li DKB, the UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:662-667.
7. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37:7-14.
8. Weiner HL, Hohol MJ, Khoury SJ, Dawson DM, Hafler DA. Therapy for multiple sclerosis. Neurol Clin 1995; 13:173-196.
9. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39:6-16.
10. Simon JH. Magnetic resonance imaging of multiple sclerosis lesions: measuring outcome in treatment trials. West J Med 1996; 164:502-509.
11. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995; 1:37-17.
12. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34:661-669.
13. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991; 180:467-474.
14. Hartung H-P. Immune-mediated demyelination. Ann Neurol 1993; 33:563-567.
15. Raine CS. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36(suppl.):S61-S72.
16. Raine CS, Lee SC, Scheinberg LC, et al. Adhesion molecules on endothelial cells in the central nervous system: an emerging area in the neuroimmunology of MS. Clin Immunol Immunopathol 1990; 57:173-187.
17. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424-435.
18. Rieckmann P, Martin S, Weichselbraun I, et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 1994; 44:2367-2372.
19. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990; 113:1477-1489.
20. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40:229-235.
21. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116:1077-1094.
22. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111:927-939.
23. Karlik SJ, Grant EA, Lee D, Noseworthy JH. Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig. Magn Reson Med 1993; 30:326-331.
24. Kent SJ, Karlik SJ, Rice GPA, Horner HC. A monoclonal antibody to α4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging 1995; 5:535-540.
25. Woodroofe MN. Cytokine production in the central nervous system. Neurology 1995; 45(Suppl 6):S6-10.
26. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37:611-619.
27. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37:1097-1102.
28. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41:1219-1222.
29. Burnham JA, Wright RR, Dreisbach J, Murray RS. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinaling lesions. Neurology 1991; 41:1349-1354.
30. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55:450-453.
31. Troiano R, Hafstein M, Ruderman M, Dowling P, Cook S. Effect of high dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Ann Neurol 1984; 15:257-263.
32. Isaac C, Li DKB, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988; 38: 1511-1515.
33. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25:43-49.
34. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29:548-555.
35. Koopsmans RA, Li DKB, Oger JJF, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 1989; 26:248-256.
36. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of Gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33:480-489.
37. Prineas JW, Barnard RO, Revesz, et al. Multiple sclerosis: pathology of recurrent lesions. Brain 1993; 116:681-693.
38. Barnes D, Munro PMG, Youl BD, et al. The long-standing MS lesion: a quantitative MRI and electron microscopic study. Brain 1991; 114:1271-1280.
39. Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991; 114:1013-1023.
40. Simon JH. Neuroimaging of multiple sclerosis. Neuroimaging Clin North Am 1993; 3:229-246.
41. Uhlenbrock D, Sehlen S. The value of T1-weighted images in differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE). Neuroradiology 1989; 31:203-212.
42. 1-weighted) spin-echo images. Neurology 1995; 45:1684-1690.
43. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994; 36:62-67.
44. Hiehle JF, Grossman RI, Ramer KN, et al. Magnetization transfer effects in MR-detected multiple sclerosis: comparison with gadolinium-enhanced spin-echo images and non-enhanced T1-weighted images. AJNR Am J Neuroradiol 1995; 16: 69-77.
45. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13:119-146.
46. Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988; 69:117-122.
47. Barkhof F, Scheltens P, Frequin STFM, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992; 159:1041-1047.
48. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992; 2:60-63.
49. Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994; 26(suppl.): S86-S90.
50. Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991; 114;2437-2450.
51. Simon JH, Jacobs L, Cookfair D, et al. The natural history of MS based on an annual MR snapshot: results from the MSCRG study of intramuscular recombinant interferon β-1a (abstract). Neurology 1995; 45(Suppl 4):A418.
52. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995; 45:255-260.
53. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo: II. findings in multiple sclerosis. Neurology 1993; 43:2632-2637.
54. Khoury SJ, Guttman CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994; 44:2120-2124.
55. DeStefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38:901-909.
56. Losseff NA, McDonald WI, Miller DH, Thompson AJ. Spinal cord atrophy in multiple sclerosis: a new reproducible and sensitive MRI technique to monitor disease progression (abstract). (Proceedings of the MS Society of Great Britain and Northern Ireland). Multiple Sclerosis 1996; 2:28.
57. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44: 635-641.
58. Tas MW, Barkhof F, van Walderveen MAA, Polman CH, Hommes OR, Valk J. The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR Am J Roentgenol 1995; 16:259-264.
59. Nauta JJP, Thompson AJ, Brakhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994; 122:6-14.
60. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32:758-766.
61. Bastianello S, Pozzilli C, D'Andrea F, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994; 21:266-270.
62. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995; 37:113-119.
63. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344:298-301.
64. Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43:1401-1406.
65. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesions load in monitoring the evolution of multiple sclerosis. Brain 1995; 118:1601-1612.
66. Mehta RC, Pike GB, Enzmann DR. Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer. AJNR Am J Neuroradiol 1995; 16:1771-1778.
67. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996; 46:379-384.
68. Wolansky LJ, Bardini JA, Cook SD, Zimmer E, Sheffet A, Lee HJ. Triple-dose versus single dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994; 4:141-145.
69. Beck RW, Arlington J, Murtagh FR, Cleary PA, Kaufman DI, Optic Neuritis Study Group. Brain magnetic resonance imaging in acute optic neuritis. Arch Neurol 1993; 50:841-846.
70. Lee DH, Simon JH, Szumowski J, et al. Optic neuritis and orbital lesions: lipid suppressed chemical shift MR imaging. Radiology 1991; 179:543-546.
71. Simon JH, Rubinstein D, Brown M, et al. Quantitative contrast-enhanced MR imaging of the optic nerve. Acta Radiologica 1994; 35:526-531.
72. Simon JH, Rubinstein D. Contrast-enhanced fat-suppression neuroimaging. Neuroimaging Clin North Am 1994; 4:153-173.
73. Morissey SP, Miller DH, Kendall BE, et al. Prognostic significance of brain MRI at presentation with a clinically isolated syndrome suggestive of MS: a five-year follow up study. Brain 1993; 116:135-146.
74. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329:1764-1769.